» Articles » PMID: 36286421

Cytotoxic N-Methylpretrichodermamide B Reveals Anticancer Activity and Inhibits P-Glycoprotein in Drug-Resistant Prostate Cancer Cells

Overview
Journal Mar Drugs
Publisher MDPI
Specialties Biology
Pharmacology
Date 2022 Oct 26
PMID 36286421
Authors
Affiliations
Soon will be listed here.
Abstract

N-methylpretrichodermamide B (NB) is a biologically active epidithiodiketopiperazine isolated from several strains of the algae-derived fungus sp. Recently, we reported the first data on its activity in human cancer cells lines in vitro. Here, we investigated the activity, selectivity, and mechanism of action of NB in human prostate cancer cell lines, including drug-resistant subtypes. NB did not reveal cross-resistance to docetaxel in the PC3-DR cell line model and was highly active in hormone-independent 22Rv1 cells. NB-induced cell death was stipulated by externalization of phosphatidylserine and activation of caspase-3. Moreover, inhibition of caspase activity by z-VAD(OMe)-fmk did not affect NB cytotoxicity, suggesting a caspase-independent cell death induced by NB. The compound has a moderate p-glycoprotein (p-gp) substrate-like affinity and can simultaneously inhibit p-gp at nanomolar concentrations. Therefore, NB resensitized p-gp-overexpressing PC3-DR cells to docetaxel. A kinome profiling of the NB-treated cells revealed, among other things, an induction of mitogen-activated protein kinases JNK1/2 and p38. Further functional analysis confirmed an activation of both kinases and indicated a prosurvival role of this biological event in the cellular response to the treatment. Overall, NB holds promising anticancer potential and further structure-activity relationship studies and structural optimization are needed in order to improve its biological properties.

Citing Articles

The Risk of Breast Cancer between Western and Mediterranean Dietary Patterns.

Tsai H, Yu J, Hsu H, Chu C, Chang T, Hong Z Nutrients. 2023; 15(9).

PMID: 37432206 PMC: 10181478. DOI: 10.3390/nu15092057.


Marine Compounds and Cancer: Updates 2022.

Dyshlovoy S, Honecker F Mar Drugs. 2022; 20(12).

PMID: 36547906 PMC: 9783002. DOI: 10.3390/md20120759.

References
1.
Nelson P . Targeting the androgen receptor in prostate cancer--a resilient foe. N Engl J Med. 2014; 371(11):1067-9. DOI: 10.1056/NEJMe1409306. View

2.
Kelly R, Draper D, Chen C, Robey R, Figg W, Piekarz R . A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res. 2010; 17(3):569-80. PMC: 3071989. DOI: 10.1158/1078-0432.CCR-10-1725. View

3.
Samatar A, Poulikakos P . Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014; 13(12):928-42. DOI: 10.1038/nrd4281. View

4.
Xu R, Hu J . The role of JNK in prostate cancer progression and therapeutic strategies. Biomed Pharmacother. 2019; 121:109679. DOI: 10.1016/j.biopha.2019.109679. View

5.
Hu J, Wang G, Sun T . Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol. 2017; 39(5):1010428317692259. DOI: 10.1177/1010428317692259. View